Premium
This is an archive article published on June 29, 2021

Explained: How worrying is Delta Plus, a variant of Covid-19?

Covid-19 Delta Plus Variant: Delta is a SARS-CoV-2 variant of concern globally; Delta Plus, with an additional mutation, is a VoC in India. While studies are still underway, scientists say Delta Plus does not seem to be more transmissible than Delta.

Trends are unclear at present on whether the current rate of vaccination can offer protection from Delta Plus.Trends are unclear at present on whether the current rate of vaccination can offer protection from Delta Plus.

Scientists in India are keeping a close watch on the Delta Plus variant, a mutated version of the Delta variant of the SARS-CoV2 coronavirus. While the transmissibility of Delta Plus is being monitored and lab tests are underway to check vaccine effectiveness, experts have said Delta Plus does not appear to be more infectious than Delta.

What is Delta Plus variant of Covid-19?

The Delta variant, or B.1.617.2, has been largely responsible for driving the second wave of coronavirus infections, and was first identified in India. It has since mutated into the variants AY.1 and AY.2.

These sub-lineages are called Delta Plus as the Delta variant has developed additional mutations of possible importance, said Dr Anurag Agrawal, director of CSIR-Institute of Genomics and Integrative Biology. “There is a need to understand the continued evolution of the B.1.617.2 lineage of SARS-CoV2,” said Dr Sujit Singh, chief of the National Centre for Disease Control.

Delta Plus has been formed as a result of Delta acquiring a mutation called K417N in the spike protein. The K417N mutation, carried by both AY.1 and AY.2, is also found in the Beta variant or B.1.351, first reported in South Africa and classified as a variant of concern by the World Health Organization (WHO).

Newsletter Click to get the day’s best explainers in your inbox

Where has this sub-lineage been detected?

Scientists said that initially, a small number of sequences of Delta (B.1.617.2) carrying the K417N were found on the Global Initiative on Sharing All Influenza Data (GISAID). The earliest sequences were attributed to Europe through routine scanning of variation in Delta.

A report by Public Health England in the first week of June mentioned 63 genomes of Delta with K417N as identified on GISAID. These 63 genomes included one each in Canada, Germany and Russia; six in India; nine in Poland; two in Nepal; four in Switzerland; 12 in Portugal; 13 in Japan and 14 in the US.

Story continues below this ad

Is Delta Plus a variant of concern?

While the WHO lists Delta as a variant of concern, the Indian government has classified Delta Plus (AY.1) as a variant of concern in the country. Dr Agrawal said any Delta sub-lineage is a variant of concern that needs to be investigated further.

While prevalence of Delta Plus is low in India, scientists are wary of the fact that some mutations help the virus become either more transmissible, or more virulent, or both. As both AY.1 and AY.2 are descendants of Delta , they are likely to share some properties of the Delta variant, such as transmissibility. Also, the K417N mutation is present in the Beta variant, which is reported to have shown immune escape and could dodge antibodies.

Source: WHO

In terms of spread, how does Delta Plus compare with Delta?

“Studies are under way, but at present we cannot say there is an increase in transmission of the Delta Plus variant based on genomic data or lab studies,” Dr Singh said.

Dr Agrawal said Delta Plus is not rising faster than the Delta variant. However, the Centre is keeping a close watch. Delta Plus cases have been found across 12 states, and public health response has been stepped up by enhancing testing, quick contact tracing and priority vaccination.

Story continues below this ad

According to INSACOG, a consortium of 28 labs set up by the Health Ministry to carry out genome sequencing of the virus, among the 45,000 samples from across 12 states that have been sequenced, some 48 have been found with the mutated variant, as per a media briefing on June 25.

Leading immunologist Dr Vineeta Bal stressed the importance of understanding how transmissible this variant could be. “We need to test the Delta Plus variant in tissue culture and compare it with the original Wuhan virus and the Delta variant to evaluate relative efficiency to enter cells expressing ACE-2 receptors. Whether it is more efficient or not in spreading the infection can then be extrapolated to speculate on its transmissibility,” she said.

In Maharashtra, where 21 cases were reported, Dr Pradeep Awate, state surveillance officer said they have identified 20 persons infected with Delta Plus (there has been one death). “Our investigations are underway, but there has not been an alarming rise in cases. The focus is on tracing the contacts of the index cases apart from stepping surveillance of Influenza-like illness cases in these areas and monitoring breakthrough and re-infection cases,” he said.

Can vaccination at the current rate offer protection from these?

Story continues below this ad

By now, India has given one dose to at least 19% of the population and both doses to 4%, leading virologist Prof Shahid Jameel said. Also, the rate of vaccination has doubled over the last week from an average of 3 million to over 6 million doses per day.

Experts note that even one dose of Covishield is over 70% effective in protecting from severe disease and hospitalisation against the Delta variant. But as far as Delta Plus in concerned, trends are unclear at present.

“We have to wait for more data on the mutated variant,” Dr Soumya Swaminathan, WHO chief scientist, told The Indian Express. “Vaccines are effective as of now against all variants in preventing severe disease and death. We will need more data from effectiveness studies. The good thing is that there are very few cases that have been described globally and we need to keep a close watch on this,” Dr Swaminathan had said earlier during a organised by the WHO.

Dr Bal said “the virus has to be grown and tested on the serum samples from those who are infected and recovered, and those who have been completely vaccinated to check whether the antibodies present in the serum samples can `neutralise’ the virus by comparing with a reference strain”.

Story continues below this ad

Is any extra precaution needed against this variant?

Double-masking, vaccination and zero tolerance for non-adherence to Covid-appropriate behaviour are extremely important, said Dr Shashank Joshi, an expert member of the Maharashtra Covid task force. “We cannot afford to be casual now,” Dr Shashank Joshi said.

According to Dr Anita Mathew, Mumbai-based infectious diseases specialist with Fortis Hospital, it is important to maintain physical distance and hand hygiene practices. The way forward is to keep a close watch on its potential presence in the country and ensure appropriate public health response, Dr Mathew said.

Prof Jameel noted that there is no answer to when or not a third wave can hit the country. “All would depend upon how we follow Covid-appropriate behaviour as the country opens up, how quickly we can provide good single dose vaccine coverage, and whether a far more infectious variant emerges as a driver.”

Officials at the Centre have said that given this new variant has been found across various parts of the country, it is crucial to take necessary measures and step up testing, tracking and vaccination. States were directed to take immediate containment measures in districts and clusters identified by INSACOG.

Anuradha Mascarenhas is a Senior Editor at The Indian Express, based in Pune. With a career spanning three decades, she is one of the most respected voices in Indian journalism regarding healthcare, science and environment and research developments. She also takes a keen interest in covering women's issues . Professional Background Education: A gold medalist in Communication and Journalism from Savitribai Phule Pune University and a Master’s degree in Literature. Author: She authored the biography At The Wheel Of Research, which chronicles the life and work of Dr. Soumya Swaminathan, the former Chief Scientist at the WHO. Key Focus: She combines scientific accuracy with storytelling, translating complex medical research into compelling public and human-interest narratives. Awards and Recognition Anuradha has won several awards including the Press Council of India's national award for excellence in journalism under the gender based reporting category in 2019 and the Laadli Media award (gender sensitivity -2024). A recipient of the Lokmat journalism award (gender category-2022), she was also shortlisted for the RedInk awards for excellence in journalism-2021. Her debut book At The Wheel Of Research, an exclusive biography of Dr Soumya Swaminathan the inaugural chief scientist of World Health Organisation was also nominated in the Popular Choice Category of JK Paper AUTHER awards. She has also secured competitive fellowships including the Laadli Media Fellowship (2022), the Survivors Against TB – New Research in TB Media Fellowship (2023) and is part of the prestigious 2025 India Cohort of the WomenLift Health Leadership Journey.” Recent Notable Articles (Late 2025) 1. Cancer & Specialized Medical Care "Tata Memorial finds way to kill drug-resistant cancer cells" (Nov 26, 2025): Reporting on a breakthrough for triple-negative breast cancer, one of the most aggressive forms of the disease. Discipline, diet and purpose; How a 97-year-old professor defies ageing'' (Nov 15, 2025) Report about Prof Gururaj Mutalik, the first Head of Department at Pune's B J Government Medical College who at 97 credits his longevity to healthy habits and a strong sense of purpose. 2. Environmental Health (The "Breathless Pune" Series) Long-term exposure even to 'moderate' air leads to chronic heart, lung, kidney issues" (Nov 26, 2025): Part of an investigative series highlighting that even "safe" pollution levels are damaging to vital organs. "For every 10 µg/m3 increase in PM2.5 level, there was 6-8% jump in medicine sales" (Nov 23, 2025): Using commercial data to prove the direct link between air quality and respiratory illnesses in Pune. 3. Lifestyle & Wellness News "They didn't let cancer, diabetes and heart disease stop them from travelling" (Dec 22, 2025): A collaborative piece featuring survivors who share practical tips for traveling with chronic conditions. At 17, his BP shot up to 200/120 mmHG; Lancet study flags why child and teen hypertension doubled between 2000 and 2020'' (Nov 12,2025)--A report that focusses on 17-year-old-boy's hypertensive crisis and reflects the rising global trend of high blood pressure among children and adolescents. 4. Scientific Recognition & Infrastructure For promoting sci-comm, gender diversity: IUCAA woman prof highlighted in Nature" (Nov 25, 2025): Covering the global recognition of Indian women scientists in gender studies and physics. Pune researchers find a spiral galaxy like the Milky Way from early universe'' (December 3, 2025)- A report on how Indian researchers discovered a massive galaxy that existed when the universe was just 1.5 billion years old , one of the earliest to have been observed so far. Signature Beat: Health, Science & Women in Leadership Anuradha is known for her COVID-19 reportage, where she was one of the first journalists to provide detailed insights into the Covishield and Covaxin trials. She has a dedicated interest in gender diversity in health and science, often profiling women researchers who are breaking the "leaky pipeline" in STEM fields. Her writing style is scrupulous, often featuring interviews with top-tier scientists and health experts from various institutions.   ... Read More

 

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement